Deliver Your News to the World

BD Taps Seasoned Executive and Researcher to Serve as Company’s Chief Technology Officer


Scott P. Bruder, MD, PhD, to Drive Company’s Focus on Innovation

Franklin Lakes, N.J. -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has named Scott P. Bruder, MD, PhD, as the Company’s Senior Vice President and Chief Technology Officer, effective September 1, 2007.

In this new position, Dr. Bruder will provide R&D, strategy and development leadership to BD as it focuses on advancing innovation in medical devices, diagnostics and biosciences. He will oversee the integration and alignment of the Company’s business and product technology planning with its R&D and business development activities. Dr. Bruder will report directly to BD Chairman, President and Chief Executive Officer Edward J. Ludwig.

“Dr. Bruder will be an important contributor to BD’s strategy of driving growth through innovation,” said Mr. Ludwig. “Dr. Bruder brings a wealth of scientific and industry experience that will help us chart BD’s course for the future and provide innovative tools to address pressing unmet global healthcare needs.”

Prior to joining BD, Dr. Bruder served in a variety of senior executive and scientific positions in the life sciences industry, most recently, as the Worldwide Vice President for Johnson & Johnson Regenerative Therapeutics, LLC. In that role, he developed a corporate-wide strategic plan and led the capitalization and creation of that business unit. He also oversaw the commercialization of numerous products and managed multiple business functions, including business development, research and feasibility, process development, clinical and regulatory affairs, quality, finance and human resources.

His eight-year career with Johnson & Johnson also included roles as Worldwide Vice President for DePuy Biologics, and as a Vice President within other DePuy businesses prior to that. Earlier in his career, Dr. Bruder worked for Anika Therapeutics and Osiris Therapeutics, specializing in cell and tissue therapies.

Dr. Bruder is an accomplished researcher and innovator, with more than 20 issued and pending U.S. and international patents. His research is widely published in peer-reviewed journals, and he is often called upon to lecture at international conferences, universities and industry events.

Dr. Bruder graduated Magna Cum Laude in 1984 from Brown University. He subsequently earned a doctorate in cell biology and a doctorate of medicine from Case Western Reserve University in 1990 and 1992, respectively. He received clinical training at Albert Einstein Medical Center and the University of Pennsylvania before embarking on his industrial career.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.